111954-72-4

Usage

Uses

Used in Smoking Cessation Aids:
(R)-2-AMINO-5-(3-PYRIDYL)PENTANE is used as a therapeutic agent for smoking cessation. It helps to reduce the cravings and withdrawal symptoms associated with nicotine addiction, making it easier for individuals to quit smoking. This application is crucial in promoting public health and reducing the prevalence of smoking-related diseases.
Used in Neurological Disorder Treatment:
In the pharmaceutical industry, (R)-2-AMINO-5-(3-PYRIDYL)PENTANE is used as a potential treatment for certain neurological disorders. Its psychoactive properties have shown promise in managing conditions such as Alzheimer's disease, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). The precise mechanisms of action are still under investigation, but nicotine's ability to modulate neurotransmitter systems may contribute to its therapeutic effects.

InChI:InChI=1/C10H16N2/c1-9(11)4-2-5-10-6-3-7-12-8-10/h3,6-9H,2,4-5,11H2,1H3/t9-/m1/s1

Upstream product

• 111848-81-8 α-methyl-3-pyridinebutanamine 
• 119981-04-3 alpha-methyl-3-pyridinebutanol 
• 81939-73-3 (2S)-2-hydroxypent-4-yne 
• 90874-88-7 5-pyridin-3-yl-pentan-2-one 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 111848-82-9 (R,R)-α-hydroxy-N-<1-methyl-4(3-pyridinyl)butyl>benzeneacetamide 
• 152613-95-1 (R)-3-(4-azidopentyl)pyridine 
• 152613-93-9 (S)-α-methyl-3-pyridinebutyl butyrate 
• 152533-15-8 (R,S)-α-methyl-3-pyridinebutyl butyrate 
• 152613-92-8 (S)-α-methyl-3-pyridinebutyl acetate 
• 152533-14-7 (R,S)-α-methyl-3-pyridinebutyl acetate 
• 152613-94-0 (S)-α-methyl-3-pyridinebutanol methanesulfonate 
• 142930-52-7 (R,S)-4-hydroxy-1-(3-pyridinyl)-1-pentanone 
• 152613-90-6 (S)-5-(3-pyridinyl)-4-pentyn-2-ol 

Downstream Products

• 120555-35-3 [R-(2E,4Z)]-5-(3-fluorophenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-decadienamide 
• 120555-31-9 Ro 24-0238 
• 120555-28-4 [R-(E,E)]-5-(3-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-nonadienamide 
• 120553-65-3 [R-(E)]-5,5-bis(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-pentadienamide 
• 120553-55-1 [R,S-(E)]-5,5-bis(3-fluorophenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4-pentadienamide 

Relevant academic research and scientific papers

SYNTHESIS OF AN ORALLY ACTIVE PAF ANTAGONIST OF THE N-PENTADIENAMIDE CLASS

The PAF antagonist -5-(4-methoxyphenyl)-N--2,4-decadienamide (2) was synthesized from (S)-α-methyl-3-pyridinebutanol (14), which was obtained either from ethyl lactate or by enantioselective kinetic hydrolysis of its racemate using the lipase derived from Pseudomonas cepacia (syn.P. fluorescens).Mesylation of 14, followed by azide displacement and hydrogenation, produced amine (7), which was coupled with the p-nitrophenol ester (8) to give 2.The direct coupling of (E,E)-5-(4-methoxyphenyl)-2,4-decadienoic acid (27) with azide(24) in the presence of tri-n-butylphosphine also gave 2.Acid (27) was prepared by a vinylogous Reformatsky reaction between ketone (25) and methyl 4-bromocrotonate.

Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors

The invention relates to compounds of the formula STR1 wherein Y and Y' are hydrogen or taken together are O or S, *A is paraphenylene or *----(CH2)n --(X)s --(CH2)r ----, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, s is an integer from 0 to 1, provided that when s is 1, n+m must be at least 2, t is an integer from 0 to 10, R1 and R2, independently, are lower alkyl, lower alkenyl or aryl, or one of R1 or R2 is hydrogen and the other is STR2 wherein W is STR3 --CH2 --CH2 --, --CH2 --, O, S, or STR4 and X1 is lower alkyl, phenyl unsubstituted or mono-, di- or trisubstituted by lower alkoxy, lower alkyl or halogen, and X2, X3 and X4, independently, are hydrogen, lower alkyl, lower alkoxy or halogen, R3 is hydrogen, lower alkyl or aryl, R4 is hydrogen, lower alkyl, aryl, aryl-lower alkyl or acyl, R5 is hydrogen or lower alkyl, R6 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 6-membered heteroaromatic radical containing one or two nitrogen atoms, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R5 and R6 are different, their enantiomers and racemic mixtures thereof, when R1 and R2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof.

Substituted n-[(pyridyl)alkyl]aryl-carboxamide

The invention relates to compounds of the formula STR1 wherein *B is STR2 Y is O or S, *A is *--(CH2)n --(X)m --(CH2)r --, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, provided that when m is 1, then n must be at least 1, X is O or S, R1 and R4, independently, are hydrogen, lower alkyl, hydroxy or lower alkoxy, provided that when *B is other than STR3 at least one of R1 and R4, and one of R6 and R7 must be hydrogen, R2 and R3 are independently hydrogen, lower alkyl, cycloalkyl, halogen, nitro, lower alkoxy, lower alkenyl, lower alkynyl or aryl, R5 and R6, independently are hydrogen or lower alkyl, R7 is hydrogen, lower alkyl, cycloalkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R6 and R7 are different, their enantiomers and racemic mixtures thereof, and pharmaceutical acceptable acid addition salts thereof. The compounds of formula I exhibit activity as Platelet Activating Factor (PAF) antagonists and are, therefore, useful as agents for the prevention and treatment of vascular diseases, pulmonary diseases, dermatological disorders, transplant rejection, immunological disorders and inflammatory conditions.

Pyridoquinazolinecarboxamide Derivatives as Platelet Activating Factor Antagonists

A series of N-pyridoquinazolines were evaluated for their ability to inhibit the binding of radiolabeled platelet activating factor (PAF) to its receptor on dog platelets.The most potent compounds in this series were found to be

Cyclopropylpropenamides

The invention relates to compounds of the formula STR1 Y is O or S, *A is paraphenylene or *--(CH2)n --(X)m --(CH2)r --, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R1 and R2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het or aryl, *E is STR2 or --(CH2)k -- wherein k is an integer from 0 to 4, R3, R4 and R8 are independently hydrogen or lower alkyl, R5 and R6, independently are hydrogen or lower alkyl, R7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and their enantiomers, diastereomers and racemic mixtures thereof, as well as when *E is STR3 their geometric isomers, and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.

Pentadieneamides

Compounds of the formula STR1 Y is O ir S, *A is paraphenylene or *----(CH2)n----(X)m --(CH2)r ----, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R1 and R2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het, aryl, R3, R4 and R8, independently, are hydrogen, lower alkyl, aryl, R5 and R6, independently, are hydrogen or lower alkyl, R7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R6 and R7 are different, their enantiomers and racemic mixtures thereof, when R1 and R2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof, are described. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characerized by excess platelet activating factor or for the prevention and treatment of cardiovascular disease, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.